Filing Flows › NewAmsterdam Pharma Co N.V. (NAMS) › Q3 2025
NewAmsterdam Pharma Co N.V. (NAMS) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
NewAmsterdam Pharma Co N.V. (NAMS) reported revenue of $348K for the third quarter 2025 (Q3 2025), -99% from a year earlier and -98% from the quarter before.
NewAmsterdam Pharma Co N.V., Q3 2025: revenue $348K (-99% year over year), net loss $72.0M, operating cash flow −$32.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $348K | -98% | -99% |
| Operating profit | −$55.1M | — | — |
| Net earnings | −$72.0M | — | — |
| Operating cash flow | −$32.8M | — | — |
What changed
Revenue was $348K in Q3 2025, down 99% year over year and down 98% from the previous quarter.
Operating costs exceeded revenue by $55.1M, an operating margin of -15845.7%. Total costs grew 3% against a revenue fall of 99%. The fastest-growing cost line was SG&A (+33%). The quarter ended with a net loss of $72.0M, wider than the previous quarter's $17.4M loss.
Operating cash flow was −$32.8M. Non-cash charges added back $64K of depreciation and amortization and $15.0M of share-based compensation. Working capital and other items added $24.2M. Capital expenditures of $42K exceeded it, leaving free cash flow of −$32.8M.
Questions
What was NewAmsterdam Pharma Co N.V.'s revenue in the third quarter 2025?
NewAmsterdam Pharma Co N.V.